The FDA assessed the security and performance of atidarsagene autotemcel determined by knowledge from 37 kids who received atidarsagene autotemcel in two one-arm, open-label clinical trials As well as in an expanded access method.[7] Children who received procedure with atidarsagene autotemcel have been in comparison with untreated children (all-na